Actionable Insights Delivered Through Medical Data-Guided NGS Panel Design | GenomeWeb
March 17, 2016
Sponsored by

Actionable Insights Delivered Through Medical Data-Guided NGS Panel Design


Scientific Director, Cytogenetics; Technical Director, Molecular Pathology/FISH; Legacy Health, Oregon

Product Director, NGS, Qiagen

Clinical Research Insights from the GeneReader NGS System

While next-generation sequencing has proven to be a very useful tool in basic research, two major hurdles remain for its broad adoption in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities. 

This webinar discussed Qiagen's approach to address these two issues. The Qiagen proprietary Knowledge Base was used to design a tumor panel to identify aberrations of value for clinical research. The GeneReader NGS System was then used to deliver clinical research insights in a laboratory setting. Testing was conducted with a set of colorectal cancer samples, and results confirmed with alternative testing platforms. 

Our first speaker, Yassmine Akkari, Scientific Director of Molecular Pathology at Legacy Health, shared her experience of NGS panel-based testing, and some of the challenges. She also spoke about the Qiagen Actionable Insights Panel design process, and how this unique process led to robust content focused on variants of clinical significance. 

Yi Kong, Product Director, NGS, Qiagen, shared some of the data generated using the Actionable Insights Tumor Panel and the GeneReader NGS System, as part of a collaboration between Qiagen and the Broad Institute. 

The Qiagen GeneReader NGS System is a fully integrated sequencing workflow, engineered specifically for clinical research purposes. This turnkey solution is purpose-built, focusing on the assays that matter most. Learn more about the GeneReader NGS System here

Sponsored by

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Sponsored by

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Sponsored by
Agilent Technologies

This online seminar will discuss how improvements on the front end and back end of the sequencing workflow can lead to better RNA-seq results.


This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.